Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010

Item Type:	Review
Title:	Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010
Creators Name:	Brennecke, B. and Gazzi, T. and Atz, K. and Fingerle, J. and Kuner, P. and Schindler, T. and de Weck, G. and Nazaré, M. and Grether, U.
Abstract:	The G-protein-coupled cannabinoid receptor type 2 (CB(2)R) is a key element of the endocannabinoid (EC) system. EC/CB(2)R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB(2)R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB(2)R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB(2)R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation®.
Keywords:	Agonist, Cannabinoid Receptor Type 1, Cannabinoid Receptor Type 2, Endocannabinoids, Endocannabinoid System, G Protein-Coupled Receptor, Animals
Source:	Pharmaceutical Patent Analyst
ISSN:	2046-8954
Publisher:	Future Science
Volume:	10
Number:	3
Page Range:	111-163
Date:	May 2021
Official Publication:	https://doi.org/10.4155/ppa-2021-0002
PubMed:	View item in PubMed

Repository Staff Only: item control page